Current Targeted Therapy for Metastatic Colorectal Cancer

被引：81

作者：

Ohishi, Tomokazu ^{[1
,2
]}

Kaneko, Mika K. ^{[3
]}

Yoshida, Yukihiro ^{[4
]}

Takashima, Atsuo ^{[5
]}

Kato, Yukinari ^{[3
,6
]}

Kawada, Manabu ^{[2
]}

机构：

[1] Microbial Chem Res Fdn, Inst Microbial Chem BIKAKEN, 18-24 Miyamoto, Numazu, Shizuoka 4100301, Japan

[2] Microbial Chem Res Fdn, Inst Microbial Chem BIKAKEN, Lab Oncol, 3-14-23 Kamiosaki,Shinagawa Ku, Tokyo 1410021, Japan

[3] Tohoku Univ, Dept Antibody Drug Dev, Grad Sch Med, 2-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan

[4] Natl Canc Ctr, Dept Thorac Surg, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[5] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Chuo Ku, Tokyo 1040045, Japan

[6] Tohoku Univ, Dept Mol Pharmacol, Grad Sch Med, 2-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 02期

基金：

日本学术振兴会;

关键词：

colorectal cancer; targeted therapy; clinical trial; GROWTH-FACTOR RECEPTOR; WILD-TYPE KRAS; MONOCLONAL-ANTIBODY THERAPY; FOLFIRI PLUS BEVACIZUMAB; POSITIVE SOLID TUMORS; 1ST-LINE TREATMENT; OPEN-LABEL; RAS MUTATIONS; PHASE-III; CETUXIMAB TREATMENT;

D O I：

10.3390/ijms24021702

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or chemotherapy for patients with metastatic CRC (mCRC) were accepted as the main therapeutic strategies until the early 2000s, when targeted drugs, like cetuximab and bevacizumab, were developed. The use of targeted drugs in clinical practice has significantly increased patients' overall survival. To date, the emergence of several types of targeted drugs has opened new possibilities and revealed new prospects for mCRC treatment. Therapeutic strategies are continually being updated to select the most suitable targeted drugs based on the results of clinical trials that are currently underway. This review discusses the up-to date molecular evidence of targeted therapy for mCRC and summarizes the Food and Drug Administration-approved targeted drugs including the results of clinical trials. We also explain their mechanisms of action and how these affect the choice of a suitable targeted therapy.

引用

页数：19

共 167 条

[1] ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer [J].

Akhoundova, Dilara ;

Hussung, Saskia ;

Sivakumar, Smruthy ;

Topfer, Antonia ;

Rechsteiner, Markus ;

Kahraman, Abdullah ;

Arnold, Fabian ;

Angst, Florian ;

Britschgi, Christian ;

Zoche, Martin ;

Moch, Holger ;

Weber, Achim ;

Sokol, Ethan ;

Fritsch, Ralph M. .

INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (12) :2161-2171

[2] Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 [J].

Allegra, Carmen J. ;

Rumble, R. Bryan ;

Hamilton, Stanley R. ;

Mangu, Pamela B. ;

Roach, Nancy ;

Hantel, Alexander ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) :179-+

[3] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[4] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[5] Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer [J].

Amatu, A. ;

Sartore-Bianchi, A. ;

Bencardino, K. ;

Pizzutilo, E. G. ;

Tosi, F. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2019, 30 :VIII5-VIII15

[6] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[7]

[Anonymous], 2004, FDA Consum, V38, P17

[8]

[Anonymous], 2012, ONCOLOGY-NY, V26, P896

[9]

[Anonymous], 2012, ONCOLOGY-NY, V26, P842

[10]

[Anonymous], 2007, FDA Consum, V41, P5

← 1 2 3 4 5 6 7 8 9 10 →